Topical application of amelogenin extracellular matrix protein in non-healing venous ulcers [¯yileşmeyen venöz ülserlerde topikal amelogenin ekstrasellüler matriks protein uygulamasi]

Basit Öğe Kaydı
dc.contributor.authorAbud B.
dc.contributor.authorKaraarslan K.
dc.contributor.authorKaraarslan I.K.
dc.contributor.authorTalay S.
dc.contributor.authorTurhan S.
dc.date.accessioned2019-10-26T21:30:29Z
dc.date.available2019-10-26T21:30:29Z
dc.date.issued2014
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground and Design: Treatment of chronic venous ulcers of the lower extremity is still an important difficulty. The principal treatment of these ulcers includes compression therapy, local wound care and surgery. Unresponsiveness to these standard treatments is a frequent situation with negative effects on life quality and reductions in personal productivity. Therefore, there is a need for new applications to increase the effectiveness of treatment in treatment-resistant cases. In the present study, we retrospectively evaluated the results of topical application of amelogenin extracellular matrix protein in resistant venous ulcers. Materials and Methods: We analyzed the records of patients with treatment-resistant venous ulceration who were treated with amelogenin extracellular matrix protein between June 2011 and December 2012. Results: 26 patients (21 male and 5 female) with a total number of 28 ulcers (24 patients with 1 ulcer, 2 patients with two ulcers) were evaluated. The patients were treated with topically applied amelogenin extracellular matrix protein and regional four bandage compression. Bandages were changed weekly. Each cure continued for six weeks. In fourteen patients (15 ulcers), we observed a complete healing by the end of the first cure. In another twelve cases (13 ulcers), the same period resulted with a reduction in wound diameter. We continued to the second cure for these patients. By the end of the second cure, complete healing was achieved in five cases (6 ulcers). Conclusion: Topical application of amelogenin extracellular matrix protein may be considered as an effective therapeutic choice for refractory venous ulcers. (Turkderm 2014; 48: 237-41).en_US
dc.identifier.doi10.4274/turkderm.60973
dc.identifier.endpage241en_US
dc.identifier.issn1019214X
dc.identifier.issn1019-214Xen_US
dc.identifier.issue4en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage237en_US
dc.identifier.urihttps://doi.org/10.4274/turkderm.60973
dc.identifier.urihttps://hdl.handle.net/11454/17630
dc.identifier.volume48en_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.publisherIstanbul Assoc. of Dermatology and Venerologyen_US
dc.relation.ispartofTurkderm Deri Hastaliklari ve Frengi Arsivien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAmelogenin extracellular matrix proteinen_US
dc.subjectChronic venous insufficiencyen_US
dc.subjectVenous ulcusen_US
dc.titleTopical application of amelogenin extracellular matrix protein in non-healing venous ulcers [¯yileşmeyen venöz ülserlerde topikal amelogenin ekstrasellüler matriks protein uygulamasi]en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu